New hope for Hard-to-Treat lung cancer: targeted drug combo enters human trials

NCT ID NCT05482568

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two new drug combinations for people with advanced non-small cell lung cancer that has a HER2 mutation. The drugs are SHR-A1811 (given by IV) combined with either pyrotinib (a pill) or SHR-1316 (another IV drug). The trial has two parts: first, finding the safest dose, and second, seeing how well the combination works. About 324 participants are being recruited at multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-A1811 (a targeted drug) combined with either pyrotinib (oral) or SHR-1316 (intravenous)
What this could lead to: If successful, this could provide a new treatment option for people with advanced HER2-positive lung cancer, potentially shrinking tumors and extending life.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the benefits and risks are not yet proven. Side effects from the drug combinations are possible and will be closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Shanghai Chest hospital
RECRUITING

Shanghai, Shanghai Municipality, 200030, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.